Neurobiological Technologies, Inc. (NTII) Moves Up Clinical Trial of Stroke Drug
Neurobiological Technologies, Inc. (NASDAQ: NTII) announced that a recent meeting with the U.S. Food and Drug Administration to discuss a Phase 3 Clinical trial for its Viprinex was encouraging. As a result, the company will consolidate data and patients from its two other trials into a single Phase 3 pivotal trial to be completed by mid-2009. Viprinex is designed to assist with the treatment of acute ischemic stroke. Interim trial results are now expected in January 2009. "Since the two concurrent Phase 3 studies employ the same protocol and patient entry criteria, the validity of the single merged study remains…